Acrivon Q2 FY26 net loss narrows 14.48% to $18 million
Reuters2026/08/12 20:08Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Acrivon Therapeutics posted a Q2 net loss of USD 18 million, narrowing from USD 21 million a year earlier.
- R&D expense fell to USD 13.8 million from USD 16.2 million, on non-recurring ACR-368 milestone costs booked in 2025.
- G&A expense declined to USD 4.8 million from USD 6.5 million, driven by lower employee-related costs including stock-based compensation.
- Cash, cash equivalents, marketable securities totaled USD 90 million at June 30, expected to fund operations into Q4 2027.
- ACR-368 Phase 2b interim analysis remains on track for H2 2026; ACR-2316 moved into randomized dose expansion with 120 mg and 160 mg.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808958) on August 12, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Quaker Houghton EVP and Chief Growth Officer Jeewat Bijlani exits Sept. 30
Reuters•2026/09/08 20:34
Bread Financial amends JPMorgan-led credit agreement for USD 700 million revolver
Reuters•2026/09/08 20:34
Brinker director Frances L. Allen disposes of 500 shares for $117,250
Reuters•2026/09/08 20:34
Column Group IV GP reports purchase of 89,200 Eikon Therapeutics shares valued at $1.03 million
Reuters•2026/09/08 20:34
Crypto prices
More
Bitcoin
BTC
$78,504.9
-0.89%
Ethereum
ETH
$2,485.3
-0.17%
Tether USDt
USDT
$0.9999
+0.01%
BNB
BNB
$749.87
+1.45%
XRP
XRP
$1.42
+1.48%
USDC
USDC
$0.9999
-0.01%
Solana
SOL
$103.43
-0.51%
TRON
TRX
$0.3381
+1.03%
Hyperliquid
HYPE
$84.35
-1.23%
Zcash
ZEC
$1,148.17
-0.78%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now